methyl 2-((4-chloro-2-nitrophenyl)thio)benzoate | 92161-65-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: methyl 2-((4-chloro-2-nitrophenyl)thio)benzoate
• 英文别名: 2-(4-chloro-2-nitro-phenylsulfanyl)-benzoic acid methyl ester；2-(4-Chlor-2-nitro-phenylmercapto)-benzoesaeure-methylester；2-(4-chloro-2-nitro-phenylsulfany)-benzoic acid methyl ester；2-nitro-4-chloro-2'-methoxycarbonyl-diphenylsulfide；methyl 2-(4-chloro-2-nitrophenylthio)benzoate；4'-Chlor-2'-nitro-diphenylsulfid-carbonsaeure-(2)-methylester；Methyl 2-[(4-chloro-2-nitrophenyl)thio]benzoate；methyl 2-(4-chloro-2-nitrophenyl)sulfanylbenzoate
• CAS: 92161-65-4
• 化学式: C₁₄H₁₀ClNO₄S
• mdl: MFCD08582838
• 分子量: 323.757
• InChiKey: BLMSDYLLYNMPHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  81 °C(Solv: methanol (67-56-1))
• 沸点：
  416.6±45.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  97.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-((4-chloro-2-nitrophenyl)thio)benzoate 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 2-(4-chloro-2-nitrophenylsulfanyl)benzoic acid
  参考文献：
  名称：

  铁催化的亚氨基酰氯与格利雅试剂的交叉偶联。

  摘要：

  [反应：见正文]描述了格氏试剂与亚氨基酰氯之间一般的，高产率的快速铁催化的交叉偶联反应。这些反应通常在5分钟内完成，使用THF-NMP溶剂混合物中的5％铁催化剂可产生71-6％的高收率。功能化的亚氨酰氯（例如R = CO（2）Me）的收率极高（89％）。

  DOI：

  10.1021/ol0600234
• 作为产物：
  描述：

  5-氯-2-氟硝基苯 、 硫代水杨酸甲酯 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 methyl 2-((4-chloro-2-nitrophenyl)thio)benzoate
  参考文献：
  名称：

  铁催化的亚氨基酰氯与格利雅试剂的交叉偶联。

  摘要：

  [反应：见正文]描述了格氏试剂与亚氨基酰氯之间一般的，高产率的快速铁催化的交叉偶联反应。这些反应通常在5分钟内完成，使用THF-NMP溶剂混合物中的5％铁催化剂可产生71-6％的高收率。功能化的亚氨酰氯（例如R = CO（2）Me）的收率极高（89％）。

  DOI：

  10.1021/ol0600234

文献信息

• BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
  申请人：ALLERGAN, INC.

  公开号：US20130231338A1

  公开（公告）日：2013-09-05

  The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

  本发明涉及新型苯并呋喃-2-磺酰胺衍生物，制备它们的方法，含有它们的药物组合物以及它们作为化学受体调节剂的药用。
• Dopamine receptor ligands
  申请人：Allelix Biopharmaceuticals Inc.

  公开号：US05538965A1

  公开（公告）日：1996-07-23

  Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings; X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--N(C.sub.1-4 alkyl).sub.2, C.dbd.CHCl, C.dbd.CHCN, N-C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO; X.sub.2 -- is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--; R.sub.1 represents C.sub.1-4 alkyl; Y is selected from CH and N; n is 0, 1 or 2; q is 1 or 2; R.sub.2 is C.sub.1-6 alkyl optionally incorporating a heteroatom selected from N, O and S; D is cyclohexane or benzene; and E is a saturated or unsaturated 5- or 6-membered heterocycle incorporating 1, 2 or 3 heteroatoms selected from O, N, and S, wherein E is optionally substituted with 1 or 2 substituents selected from halogen, C.sub.1-4 alkyl and halogen-substituted C.sub.1-4 alkyl; and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.

  本文描述了一般式为：##STR1##的D4受体选择性化合物，其中：A和B分别选择，可选择性取代，饱和或不饱和的5-或6-成员的同源或异源环；X.sub.1从CH.sub.2，O，NH，S，C.dbd.O，CH--OH，CH--N(C.sub.1-4烷基).sub.2，C.dbd.CHCl，C.dbd.CHCN，N-C.sub.1-4烷基，N-乙酰基，SO.sub.2和SO中选择；X.sub.2--从N.dbd.，CH.sub.2--，CH.dbd.，C(O)--，O--和S--中选择；R.sub.1代表C.sub.1-4烷基；Y从CH和N中选择；n为0、1或2；q为1或2；R.sub.2为C.sub.1-6烷基，可选择性地包含从N、O和S中选择的杂原子；D为环己烷或苯；E为饱和或不饱和的5-或6-成员的异源环，包含从O、N和S中选择的1、2或3个杂原子，其中E可选择性地取代为1或2个从卤素、C.sub.1-4烷基和卤素取代的C.sub.1-4烷基中选择的取代基；以及它们的酸盐、溶剂合物和水合物。还描述了它们作为多巴胺受体配体用于鉴定和在药物筛选计划中的应用，以及作为药物治疗D4受体所涉及的精神分裂症等适应症。
• Muscarinic receptor ligands
  申请人：Allelix Biopharmaceuticals, Inc.

  公开号：US05561127A1

  公开（公告）日：1996-10-01

  Described herein are D4 receptor-selective compounds of the general formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings; X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--NEt.sub.2, C.dbd.CHCl, C.dbd.CHCN, N--C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO; X.sub.2 --is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--; n is 1 or 2; and Z is selected from C.sub.1-6 alkyl optionally substituted with a substituent selected from OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the M1/M2 receptor is implicated, such as schizophrenia, is also described.

  本文描述了一般式I的D4受体选择性化合物：##STR1##其中：A和B分别选择，可选择取代的饱和或不饱和的5-或6-成员同源或异源环；X.sub.1选择自CH.sub.2、O、NH、S、C.dbd.O、CH--OH、CH--NEt.sub.2、C.dbd.CHCl、C.dbd.CHCN、N--C.sub.1-4烷基、N-乙酰基、SO.sub.2和SO；X.sub.2--选择自N.dbd.、CH.sub.2--、CH.dbd.、C(O)--、O--和S--；n为1或2；Z选择自C.sub.1-6烷基，可选择用OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基中的取代基取代；以及它们的酸盐、溶剂合物和水合物。还描述了它们作为多巴胺受体配体用于药物筛选程序和药物治疗M1/M2受体所涉及的疾病，如精神分裂症。
• Über Dibenzo-thiazepin-Derivate und ihre pharmakologische Wirkung
  作者：R. Jaques、A. Rossi、E. Urech、H. J. Bein、K. Hoffmann

  DOI：10.1002/hlca.19590420422

  日期：——

  The synthesis and pharmacological activity of basically substituted dibenzothiazepines are described. They possess interesting antihistamine and antiserotonine activity. By varying the substituents in the benzene nuclei, and by a suitable choice the basic side chains, the specifity and activity of some derivatives could be increased considerably, especially with the dibenzothiazepinones.

  描述了基本取代的二苯并硫氮杂s的合成和药理活性。它们具有有趣的抗组胺药和抗血清素活性。通过改变在苯核的替代物，并且通过合适的选择的碱性侧链，一些衍生物的特异性和活性，可以显着地增加，特别是与dibenzothiazepinones。
• Bicyclic nonane and decane compounds having dopamine receptor affinity
  申请人：Allelix Biopharmaceuticals

  公开号：US05703072A1

  公开（公告）日：1997-12-30

  Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, substituted or unsubstituted, unsaturated 5- or 6-membered, homo- or heterocyclic rings; X.sub.1 is selected from O, S, SO, SO.sub.2, CH.sub.2, C.dbd.O, CH--OH, CH--N(C.sub.1-4 alkyl).sub.2, C.dbd.CHCl, and C.dbd.CHCN; X.sub.2 --- is selected from N.dbd., CH.sub.2 --, CH.dbd. and C(O)--; n is 1 or 2; R.sub.1 is selected from H and the .alpha.-carbon side chain of an amino acid; R.sub.2 and R.sub.3 are selected independently from H, OH, --NH.sub.2, --C(O)NH.sub.2 .dbd.O, .dbd.S,halo,cyano, C.sub.1-9 alkyl, C.sub.1-9 alkoxy, C.sub.1-4 alkylS--, C.sub.1-4 alkylSO--, C.sub.1-4 alkylSO.sub.2 --, phenoxy, benzyloxy and piperonyloxy; and H* is in either the R- or the S-configuration, and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.

  本文描述了一般公式为：##STR1##的D4受体选择性化合物，其中：A和B分别选择自取代或未取代的不饱和5-或6-成员同源或异源环；X.sub.1选择自O、S、SO、SO.sub.2、CH.sub.2、C.dbd.O、CH--OH、CH--N(C.sub.1-4烷基).sub.2、C.dbd.CHCl和C.dbd.CHCN；X.sub.2选择自N.dbd.、CH.sub.2 --、CH.dbd.和C(O)--；n为1或2；R.sub.1选择自H和氨基酸的α-碳侧链；R.sub.2和R.sub.3分别选择自H、OH、--NH.sub.2、--C(O)NH.sub.2.dbd.O、.dbd.S、卤素、氰基、C.sub.1-9烷基、C.sub.1-9烷氧基、C.sub.1-4烷基S--、C.sub.1-4烷基SO--、C.sub.1-4烷基SO.sub.2 --、苯氧基、苄氧基和香豆氧基；H*为R-或S-构型，并描述了它们的酸盐、溶剂合物和水合物的用途。还描述了它们作为多巴胺受体配体用于药物筛选方案和药用于治疗D4受体涉及的症状，如精神分裂症。